<p>In the development of Parkinson’s disease (PD), the changes that will lead to neurodegeneration take place in the brain long before patients show any symptoms. But without a test that can detect these changes, it’s difficult to intervene early to more effectively slow disease progression. </p>
<p>Researchers from the <a href="http://brighamandwomens.org/">Brigham and Women’s Hospital</a>, a founding member of <a href="http://massgeneralbrigham.org/">Mass General Brigham</a>, <u>and</u> <a href="https://wyss.harvard.edu/">Wyss Institute for Biologically Inspired Engineering at Harvard University</a> have developed a molecular assay platform that they successfully applied to patient samples to detect and quantify single ⍺-synuclein fibrils, the pathogenic aggregates of ⍺-synuc